Gastric Cancer Management and Outcomes
Open access
Peer reviewed
Scollr summary
What this paper is about
The optimal treatment for cT2N0 gastric cancer should include surgery and chemotherapy, and consideration should be given to a strategy of upfront surgical resection and adjuvant therapy rather than perioperative chemotherapy.
Full abstract
Read the full abstract
INTRODUCTION: Randomized controlled trials have demonstrated substantial benefit of perioperative chemotherapy (PC) and surgery for locally advanced gastric adenocarcinoma. Patients with clinical T2N0 (cT2N0) gastric adenocarcinoma were included in these trials, but the benefit of PC remains unclear in this intermediate-stage disease due to the small number of patients included. The goal of this study was to determine the role and sequencing of chemotherapy for resected cT2N0 gastric adenocarcinoma. METHODS: The National Cancer Database from 2004 to 2020 was used to identify patients with cT2N0 gastric adenocarcinoma who underwent surgical resection. Patients were stratified by receipt of chemotherapy into three groups: (1) no chemotherapy, (2) perioperative chemotherapy (PC), and (3) adjuvant chemotherapy (AT). The primary outcome was overall survival. RESULTS: Of 3676 patients with cT2N0 gastric adenocarcinoma, 61.3% received no chemotherapy, 19.4% received PC, and 19.2% received AT. Of the 2961 patients who underwent upfront surgical resection, 28.8% (854) were upstaged on final pathology. Multivariable survival analysis revealed that both PC and AT were associated with a decreased mortality compared to no chemotherapy (0.64 and 0.68, respectively, p < 0.001). AT was associated with a 21% decrease in mortality compared to PC (HR 0.79, p = 0.015). CONCLUSION: Patients presenting with cT2N0 gastric adenocarcinoma benefit from chemotherapy in addition to surgery, although a minority of patients received guideline concordant care. Patients who received adjuvant chemotherapy had superior outcomes compared to those who received perioperative chemotherapy. The optimal treatment for cT2N0 gastric cancer should include surgery and chemotherapy, and consideration should be given to a strategy of upfront surgical resection and adjuvant therapy rather than perioperative chemotherapy.
Direct answer
What can I do from this paper page?
Use this page to scan "Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Gastric Cancer Management and Outcomes research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Olecki2026Optimal,
title = {Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?},
author = {Elizabeth J. Olecki and Rolfy Perez Holguin and Matthew Dixon and June S. Peng},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70354},
url = {https://doi.org/10.1002/jso.70354}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Gastric Cancer Management and Outcomes research papers?
Follow Gastric Cancer Management and Outcomes research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app